CBUS

Cibus Inc. Class A Common Stock (CBUS) | Rumor.io

Cibus

CBUS

Attention (50-day avg)0%

Attention rank (50-day avg)#4,635

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.53

Market capitalization112.4M

Earnings per share-1.51

Dividend yield (TTM)—

Revenue (annual)3.6M

Net income (annual)-132.2M

Social

What share of all stock conversation is about CBUS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 17

Cibus, Inc. ($CBUS) reported Q4 2025 revenue of $1.1 million, with a net loss of $25.8 million and an EPS of -$0.43.
The company's cash balance of $9.9 million is expected to fund operating expenses into late Q3 2026, with a target annual net cash usage of approximately $30 million or less in 2026.
Cibus is in a pre-revenue commercialization phase, with its Rice program advancing and planned launches in LATAM in 2027 and the U.S. in 2028.

Generated by AI

Sentiment

Of the messages about CBUS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96% +16
Bearish	—	—	—	4% -16

Bullish· Feb 17

$CBUS has a relatively low float of 41-43 million shares and an average volume of only 1.2 million shares, indicating a potential for price acceleration with increased trading activity.
The stock is experiencing a clean upside move, supported by increasing volume and trending higher prices, indicating momentum trader engagement.
The company's partnership with the John Innes Centre for a UK government innovation program, which targets a disease causing £300m in losses, is seen as a major catalyst for the stock's surge, with technical targets ranging from $481.33 to $460.38.

Bearish· Jan 17

The asset's price is prone to significant drops, with some users experiencing substantial losses.
The company's business model and leadership have been questioned, with some users expressing skepticism about its ability to succeed in the agricultural technology sector.
The asset's price action is likely to be influenced by short-term market forces, with some users predicting a sell-off or a bounce in the near future.

Generated by AI

Topics

Of the messages about CBUS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	3.3%
Announcements	—	—	—	59.34%
Controversies	—	—	—	0%
Earnings	—	—	—	2.2%
Macro	—	—	—	0.55%
Technical Analysis	—	—	—	34.62%

Jan 17

Calyxt and Cibus, Inc. ($CBUS) have announced a definitive merger agreement to create an industry-leading precision gene editing and trait licensing company.
The merger will combine the two pioneers in agriculture-based gene editing and establish one of the world's most sophisticated facilities for trait development and next-generation plant breeding.
Calyxt shareholders will own approximately 5% of the combined company, while Cibus shareholders will receive shares of Calyxt's common stock in an exchange ratio.

Generated by AI

Community

Of the messages about CBUS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	19.61%
Newcomers	—	—	100%	80.39%

Feb 17

The newcomer users are focused on the potential of CBUS stock due to its recent surge, with some attributing the move to the company's partnership with the John Innes Centre for the UK's Precision Breeding Initiative.
The partnership with the John Innes Centre is seen as a key catalyst for CBUS stock, as it utilizes the company's proprietary RTDS technology to combat Light Leaf Spot, a disease causing significant losses in the UK.
The users are also highlighting the technical resistance levels and potential targets for CBUS stock, with some noting that the company's stock has broken through key resistance levels and is now targeting higher levels, such as $460.38.

Generated by AI

News

Cibus (CBUS) Q2 2026 Earnings Call Transcript

Detailed price information for Cibus Inc (CBUS-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Quarterly Update Report

Download the Complete Report Here Cibus, Inc. (CBUS) Interoc Expands Rice Pipeline to Five Traits; Platform Revenue and Cost Discipline Advance as LATAM Launch Moves to 2028 Key Takeaways: Rice commercialization advanced as Interoc testing began and the relationship expanded from two to five traits, although initial LATAM launch timing moved to 2028. Sustainable Ingredients […] The post Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Quarterly Update Report appeared first

1mo agoYahoo Finance

Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Downloadable Quarterly Update Report

1mo agofinance.yahoo.com

Cibus, Inc. Q2 2026 Earnings Call Summary

Moby summary of Cibus, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Trait Pipeline Model ...

Despite a delayed rice launch and cash runway concerns, Cibus expands partnerships and advances regulatory approvals across key markets.

1mo agoYahoo Finance

Cibus earnings missed by $0.05, revenue fell short of estimates

1mo agoInvesting.com

Also Discussed

Investors talking about CBUS also mention

#	Name	Attention
1	Cellectis S.A. ADRCLLS	0%0
2	CYAD - Celyad Oncology S.A.	——
3	TLIS - Talis Biomedical Corporation	——
4	SANW - S&W Seed Company	——
5	BK Technologies Corporation Common StockBKTI	0%0
6	LABP - Landos Biopharma, Inc.	——
7	Petvivo Holdings IncPETV	0%-0.01
8	Corteva Inc.CTVA	0%0
9	Q32 Bio Inc.QTTB	0%+0
10	Clearside Biomedical Inc.CLSD	0%0

Cibus Inc. Class A Common Stock

Healthcare
Biotechnology

Cibus Inc. Class A Common Stock represents ownership in Cibus Inc., an agricultural biotechnology company based in San Diego, California. The company develops and licenses gene-edited plant traits for seed companies, using proprietary technologies to improve crop productivity, resilience, and sustainability. Its work centers on traits that can help address challenges such as yield performance, disease pressure, weed control, nutrient use, and climate stress across major crops including canola, rice, soybean, corn, and wheat. Cibus also develops plant traits for sustainable ingredients and other agricultural applications that support lower-input farming and more efficient production systems. As a publicly traded equity security, Cibus Inc. Class A Common Stock provides market participants with exposure to a company focused on agricultural innovation, crop trait development, and commercial licensing within the biotechnology sector.

Website

Location

6455 Nancy Ridge Drive

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about CBUS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 17

Cibus, Inc. ($CBUS) reported Q4 2025 revenue of $1.1 million, with a net loss of $25.8 million and an EPS of -$0.43.
The company's cash balance of $9.9 million is expected to fund operating expenses into late Q3 2026, with a target annual net cash usage of approximately $30 million or less in 2026.
Cibus is in a pre-revenue commercialization phase, with its Rice program advancing and planned launches in LATAM in 2027 and the U.S. in 2028.

Generated by AI

Sentiment

Of the messages about CBUS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96% +16
Bearish	—	—	—	4% -16

Bullish· Feb 17

$CBUS has a relatively low float of 41-43 million shares and an average volume of only 1.2 million shares, indicating a potential for price acceleration with increased trading activity.
The stock is experiencing a clean upside move, supported by increasing volume and trending higher prices, indicating momentum trader engagement.
The company's partnership with the John Innes Centre for a UK government innovation program, which targets a disease causing £300m in losses, is seen as a major catalyst for the stock's surge, with technical targets ranging from $481.33 to $460.38.

Bearish· Jan 17

The asset's price is prone to significant drops, with some users experiencing substantial losses.
The company's business model and leadership have been questioned, with some users expressing skepticism about its ability to succeed in the agricultural technology sector.
The asset's price action is likely to be influenced by short-term market forces, with some users predicting a sell-off or a bounce in the near future.

Generated by AI

Topics

Of the messages about CBUS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	3.3%
Announcements	—	—	—	59.34%
Controversies	—	—	—	0%
Earnings	—	—	—	2.2%
Macro	—	—	—	0.55%
Technical Analysis	—	—	—	34.62%

Jan 17

Calyxt and Cibus, Inc. ($CBUS) have announced a definitive merger agreement to create an industry-leading precision gene editing and trait licensing company.
The merger will combine the two pioneers in agriculture-based gene editing and establish one of the world's most sophisticated facilities for trait development and next-generation plant breeding.
Calyxt shareholders will own approximately 5% of the combined company, while Cibus shareholders will receive shares of Calyxt's common stock in an exchange ratio.

Generated by AI

Community

Of the messages about CBUS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	19.61%
Newcomers	—	—	100%	80.39%

Feb 17

The newcomer users are focused on the potential of CBUS stock due to its recent surge, with some attributing the move to the company's partnership with the John Innes Centre for the UK's Precision Breeding Initiative.
The partnership with the John Innes Centre is seen as a key catalyst for CBUS stock, as it utilizes the company's proprietary RTDS technology to combat Light Leaf Spot, a disease causing significant losses in the UK.
The users are also highlighting the technical resistance levels and potential targets for CBUS stock, with some noting that the company's stock has broken through key resistance levels and is now targeting higher levels, such as $460.38.

Generated by AI

Cibus

Social

Mar 17

Bullish· Feb 17

Bearish· Jan 17

Jan 17

Feb 17

Cibus (CBUS) Q2 2026 Earnings Call Transcript

Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Quarterly Update Report

Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Downloadable Quarterly Update Report

Cibus, Inc. Q2 2026 Earnings Call Summary

Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Trait Pipeline Model ...

Cibus earnings missed by $0.05, revenue fell short of estimates

Also Discussed

Cibus Inc. Class A Common Stock

Company Information

Location

Cibus (CBUS) Q2 2026 Earnings Call Transcript

Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Quarterly Update Report

Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Downloadable Quarterly Update Report

Cibus, Inc. Q2 2026 Earnings Call Summary

Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Trait Pipeline Model ...

Cibus earnings missed by $0.05, revenue fell short of estimates

Also Discussed

Social

Mar 17

Bullish· Feb 17

Bearish· Jan 17

Jan 17

Feb 17